source
- Heron sells assets to CorMedix for $145M upfront, Faeth shares plungeHeron Therapeutics announced it has sold a portfolio of assets to CorMedix for an upfront cash payment of $145 million. The transaction gives CorMedix additional product candidates and expands its…
- Zura Bio’s Phase 2 trial of tibulizumab fails, shares plungeZura Bio announced that its experimental drug tibulizumab did not meet efficacy endpoints in a Phase 2 study of a painful skin disorder. The company said that both dose levels performed no better t…